Every 8-K that AbCellera Biologics Inc. (ABCL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ABCL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABCL filings page.
AbCellera Biologics Inc. entered into an underwriting agreement for an underwritten public offering of 17,435,897 common shares at $9.75 per share and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 3,076,926 common shares at $9.74999 per warrant.
All securities are being sold by AbCellera, with expected gross proceeds of $200.0 million and estimated net proceeds of approximately $187.0 million. Each pre-funded warrant is immediately exercisable for one common share at an exercise price of $0.00001 per share and is subject to a 4.99% beneficial ownership cap, adjustable up to 19.99% with 61 days’ notice. The offering, made under a shelf registration statement on Form S-3ASR, is expected to close on or about August 14, 2026, and AbCellera has agreed to a 60-day lock-up on additional share sales, subject to exceptions.
AbCellera Biologics Inc. reported positive Phase 2 results for ABCL635, an investigational neurokinin 3 receptor (NK3R) antagonist antibody being developed as a non-hormonal, long-acting subcutaneous treatment for moderate-to-severe vasomotor symptoms (VMS) due to menopause. In a randomized, double-blind, placebo-controlled trial of 92 postmenopausal women (46 ABCL635, 46 placebo), a single 600 mg dose met the primary efficacy endpoints at week 4.
ABCL635 reduced VMS frequency by a mean of 8.8 moderate/severe hot flashes per day from baseline versus 3.5 for placebo, a placebo-adjusted difference of 5.3 and an 83% vs 33% mean percent reduction. Severity improved with a mean reduction of 1.4 points vs 0.3 for placebo, and mean percent reduction of 58% vs 12%. At week 4, 84% of ABCL635 patients rated symptoms as “Much Better” or “Moderately Better” versus 27% on placebo, and sleep disturbance scores improved with a placebo-adjusted change of -5.5 points. ABCL635 was described as well tolerated, with no serious or severe adverse events in the active arm, no meaningful liver or gastrointestinal safety signal, and headache, fatigue, and injection-site reactions as the most common events. The company plans 12-week follow-up, additional data presentations, and regulatory interactions to discuss late-stage development.
AbCellera Biologics Inc. announced it will release top-line data from its Phase 2 trial of ABCL635 for the treatment of moderate-to-severe vasomotor symptoms due to menopause on August 10, 2026, and will host an investor conference call that morning.
ABCL635 is described as a potential first-in-class, non-hormonal antibody targeting NK3R, a clinically validated G protein-coupled receptor expressed on KNDy neurons in the hypothalamus. The Phase 2 trial (NCT07118891) is a multicenter, randomized, double-blind, placebo-controlled study in approximately 80 postmenopausal women evaluating reduction in the frequency and severity of vasomotor symptoms. ABCL635 is the first program from AbCellera’s GPCR and ion channel platform to enter the clinic, having done so in July 2025.
AbCellera Biologics Inc. reported Q2 2026 financial and operational results. Total revenue was $4.1 million, compared with $17.1 million in Q2 2025, and the company posted a net loss of $55.4 million, or $(0.18) per share, versus a net loss of $34.7 million, or $(0.12) per share, a year earlier.
The company highlighted pipeline progress, including completed enrollment in the Phase 2 trial of ABCL635 with top-line data expected in August 2026, and completed dosing in the Phase 1 study of ABCL575 with data expected in Q4 2026. ABCL386 and ABCL688 are in IND-enabling activities, and partners led 35 programs with downstream participation, including 12 molecules in the clinic as of June 30, 2026.
AbCellera expanded its T-cell engager collaborations, signing a Jazz Pharmaceuticals agreement with $84 million in total upfront payments and eligibility for up to $792 million per program in option and milestone payments plus tiered royalties, and a Vertex collaboration providing $28 million in upfront payments with further milestone and royalty potential. The company emphasized a strong liquidity position with over $565 million in cash balances and marketable securities and more than $675 million in total available liquidity, including $110 million in available non-dilutive government funding.
AbCellera Biologics Inc. entered into a collaboration with Vertex Pharmaceuticals to research, develop, manufacture, and commercialize multispecific T-cell engagers for autoimmune diseases and other conditions. AbCellera will use its proprietary T-cell engager platform to lead discovery and early development.
Vertex will fund all research and development costs and will have the right to develop and commercialize therapeutic multispecific antibodies arising from the collaboration. AbCellera will receive $28 1 million in total upfront payments and is eligible for additional milestone payments and tiered royalties on net sales, with an option for AbCellera to provide development and clinical manufacturing through Phase 1 by mutual agreement.
AbCellera Biologics Inc. has appointed Lynn Seely, M.D., as a new Class III independent director on its Board of Directors. She will serve until the company’s 2029 annual meeting of shareholders and until a successor is elected and qualified or she departs earlier.
The Board determined that Dr. Seely is independent under Nasdaq rules and the company’s corporate governance guidelines. She will receive compensation under AbCellera’s Non-Employee Director Compensation Policy on the same terms as other non-employee directors, with no related-party transactions or appointment arrangements disclosed.
Dr. Seely is president and CEO of Lyell Immunopharma Inc. and previously led Myovant Sciences Inc. and served as chief medical officer of Medivation Inc., where she oversaw development of the oncology drug Xtandi. A press release with additional background is included as Exhibit 99.1.
AbCellera Biologics Inc. entered a preclinical research collaboration, option and license agreement with Jazz Pharmaceuticals to discover and develop next-generation T-cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors. The collaboration includes $56 million in upfront payments to AbCellera for two initial programs, with a commitment to start a third program within 12 months. AbCellera will receive an additional $28 million upon initiation of the third program and is eligible for up to $792 million per program in option fees and development, regulatory and commercial sales milestone payments, plus tiered royalties on net sales ranging from mid-single digits to low double-digits.
AbCellera Biologics Inc. reported the results of its annual shareholder meeting held on June 11, 2026. Shareholders elected Class III directors John S. Montalbano and Stephen R. Quake to terms ending at the 2029 annual meeting. As of the April 15, 2026 record date, 305,264,947 common shares were outstanding and entitled to vote.
Shareholders also ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, and approved, on a non-binding advisory basis, the compensation of the company’s named executive officers (Say-on-Pay). No other matters were submitted for a vote.
AbCellera Biologics Inc. announced that its Board of Directors appointed Dr. Victor Sandor as a new independent director. He will serve until the next annual meeting of shareholders and until a successor is elected and qualified, or earlier resignation or removal.
The Board determined that Dr. Sandor is independent under Nasdaq rules and the company’s Corporate Governance Guidelines. He will participate in AbCellera’s Non-Employee Director Compensation Policy on the same terms as other non-employee directors and currently has not been appointed to any Board committees.
AbCellera highlighted Dr. Sandor’s extensive oncology drug development background, including leadership roles at Array BioPharma, Incyte, Biogen, and AstraZeneca, where he contributed to multiple cancer therapy approvals. The company describes itself as a clinical-stage biotechnology firm focused on first-in-class antibody-based medicines across several therapeutic areas.
AbCellera Biologics Inc. reported first quarter 2026 results and highlighted positive interim Phase 1 data for its lead program ABCL635. Revenue rose to $8.3 million from $4.2 million in Q1 2025, while net loss narrowed slightly to $43.2 million or $(0.14) per share.
The company increased research and development spending to $46.7 million and reduced sales, general and administrative expenses to $12.3 million. AbCellera ended the quarter with approximately $655 million in total available liquidity, including $531 million in cash, cash equivalents and marketable securities and about $124 million in non‑dilutive government funding.
Interim Phase 1 data for ABCL635, a potential first‑in‑class antibody targeting NK3R for menopausal vasomotor symptoms, showed a favorable tolerability profile with no serious adverse events or liver toxicity, an estimated half‑life of about 24 days supporting once‑monthly dosing, and strong, sustained suppression of testosterone, follicle‑stimulating hormone and luteinizing hormone as biomarkers of target engagement. These findings supported advancing ABCL635 into a Phase 2 trial in postmenopausal women, with topline efficacy data expected in Q3 2026.
AbCellera Biologics Inc. reported full-year 2025 revenue of $75.1 million, up sharply from $28.8 million in 2024, while remaining loss-making as it ramps internal R&D. Net loss was $146.4 million, or $(0.49) per share, improving from a $162.9 million loss, or $(0.55) per share, in 2024.
Research and development expenses rose to $186.8 million as the company emphasized its own pipeline, while SG&A declined slightly to $83.2 million. Fourth-quarter 2025 revenue was $44.9 million, mostly from an upfront patent litigation settlement, with a quarterly net loss of $8.9 million, or $(0.03) per share.
The company highlighted its transition to a clinical-stage biotech, with ABCL635 moving into the Phase 2 portion of a Phase 1/2 trial and ABCL575 in a Phase 1 trial. Two additional candidates, ABCL688 and ABCL386, entered IND/CTA-enabling activities. As of December 31, 2025, AbCellera reported $561 million in cash, cash equivalents, and marketable securities plus about $135 million in available non-dilutive government funding, for roughly $700 million of total liquidity to support its strategy and planned clinical milestones.
AbCellera Biologics Inc. filed an update describing two investor-focused developments. The company has begun dosing the first patients in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635, signaling that this experimental therapy has advanced to the next stage of human testing.
AbCellera also posted an updated corporate presentation on its investor website, which it may use in future communications and conferences. Both the press release about ABCL635 and the new presentation are furnished as exhibits and are not treated as filed financial statements under securities law.
AbCellera Biologics Inc. disclosed that on December 18, 2025 it issued a press release announcing a settlement and patent license agreement with Bruker Corporation. This agreement resolves the patent litigation between the two companies on a global basis, ending the dispute over intellectual property rights worldwide. The press release detailing the settlement and license terms is provided as Exhibit 99.1 to this report, and the information is furnished under Regulation FD rather than filed for liability purposes.
AbCellera Biologics Inc. (ABCL) announced Board changes. On November 10, 2025, the Board appointed Stephen Quake, D.Phil., as a director, effective immediately. He will serve until the next annual meeting and has been deemed independent under Nasdaq rules and the Company’s guidelines. Dr. Quake was assigned to the Audit Committee and the Nominating and Corporate Governance Committee and will participate in the Non-Employee Director Compensation Policy on the same terms as other non-employee directors.
Also on November 10, 2025, Andrew Lo, Ph.D., resigned from the Board, effective immediately. The Company stated his resignation was not due to any disagreement. He previously served on the Audit and Nominating and Corporate Governance Committees.
AbCellera Biologics Inc. (ABCL) furnished a press release and investor presentation related to its financial and operational results for the quarter ended September 30, 2025. The company aligned the materials with its earnings call on November 6, 2025, and provided them as exhibits.
The information under Items 2.02 and 7.01 is being furnished, not filed, and is not subject to Section 18 liability nor incorporated by reference except as stated. Exhibits include 99.1 (press release) and 99.2 (corporate presentation).
AbCellera Biologics Inc. filed a report describing a leadership change in its medical organization. Sarah Noonberg, M.D., Ph.D., has been appointed as the company’s Chief Medical Officer, a key role overseeing medical strategy and clinical development. The company announced this appointment in a press release dated September 10, 2025, which is included as an exhibit to the report.
The filing classifies this as an "Other Event" and does not include financial results or transaction details. It confirms that AbCellera’s common shares trade on The Nasdaq Stock Market LLC under the symbol ABCL and that the report was signed by Chief Executive Officer Carl L. G. Hansen.